The TRIUMPH program includes seven other Phase 3 trials (TRIUMPH-1 general obesity 80 weeks, TRIUMPH-2 obesity+T2D, TRIUMPH-3 obesity+CV disease, plus T2D, OSA, and CVOT) with readouts expected during 2026
You message your doctor any time through the portal, with responses inside 24 hours
Week 1-4: 0.25 mg once weekly Weeks 5-8: 0.5 mg once weekly Weeks 9-12 (if needed): 1 mg once weekly, if further glycemic control is required Week 13 onwards (if needed): 2 mg once weekly, if your body can tolerate the previous dosage and further glycemic control is required This medication is started at 0.25 mg per week until you reach the maintenance dose
Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimers disease via the GLP-1R/SIRT1/GLUT4 pathway
For those exploring this path, regular communication with a healthcare team is critical
This program includes digital tools and medication management support for members prescribed GLP-1 drugs
.png)
